article thumbnail

Do patients care about accelerated approval drugs?

World of DTC Marketing

85% of accelerated approvals from 2010 to 2020 were for oncology indications. of approvals), cancer (35.6%), and other rare diseases (24.7%). Since then, accelerated Approval has shifted focus to oncology drugs.

Patients 200
article thumbnail

Innovation in immuno-oncology: Leading companies in microbiota restoration therapy

Pharmaceutical Technology

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’. Probiotical is a manufacturer of probiotics and synbiotics products.

Leads 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma’s outdated hiring practices

World of DTC Marketing

I often tell people that working in pharma is often frustrated as they are incredibly process-driven and that matrix organizational structures lead to very slow decision-making. The average time it takes to fill an open position is 44 days, representing a 50-percent increase since 2010.

Pharma 277
article thumbnail

Innovation in small molecules: Leading companies in quinoline derivatives as anticancer agents

Pharmaceutical Technology

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’. Exelixis is a biopharmaceutical company that focuses on the development and commercialisation of small molecules for the treatment of cancer.

Leads 92
article thumbnail

Innovation in targeted therapies: Leading companies in photodynamic cancer therapy drugs

Pharmaceutical Technology

The company’s lead asset is NBTXR3, which is based on hafnium oxide nanoparticle that is designed to destroy tumors when activated by radiotherapy. ‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Leads 72
article thumbnail

Lonza appoints new Chief Executive

European Pharmaceutical Review

Before joining Siegfried in 2010, Wienand worked at the German specialty chemicals company Evonik Industries, Lonza highlighted. Wolfgang Wienand – leading the next chapter “Wolfgang brings a wealth of knowledge and experience to Lonza, complemented by his deep scientific and strategic expertise. billion.

article thumbnail

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

A leading CB2 agonist, olorinab, displayed encouraging results when managing abdominal pain in irritable bowel syndrome (IBS) patients, but failed to meet the primary efficacy endpoints. Currently, Jazz Pharmaceuticals’s nabiximols is the only cannabinoid approved for pain, receiving approval in Israel, in August 2010.

Medical 143